CorMedix Inc. (CRMD)
| Market Cap | 621.26M +4.2% |
| Revenue (ttm) | 311.71M +617.0% |
| Net Income | 162.07M |
| EPS | 2.04 |
| Shares Out | 78.44M |
| PE Ratio | 3.88 |
| Forward PE | 15.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 858,907 |
| Open | 8.03 |
| Previous Close | 7.92 |
| Day's Range | 7.82 - 8.15 |
| 52-Week Range | 6.13 - 17.43 |
| Beta | 1.46 |
| Analysts | Strong Buy |
| Price Target | 14.83 (+87.25%) |
| Earnings Date | May 14, 2026 |
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price target is $14.83, which is an increase of 87.25% from the latest price.
News
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the...
Citizens healthcare analysts hold an analyst/industry conference call
Healthcare Analysts discuss expanding CorMedix (CRMD) Therapeutics’ Rezzayo for Prophylactic Use on an Analyst/Industry conference call to be held on April 30.
CorMedix price target raised to $14 from $13 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on CorMedix (CRMD) to $14 from $13 and keeps an Outperform rating on the shares. The company eported positive topline
CorMedix announces ReSPECT clinical trial met primary endpoint
CorMedix (CRMD) announced Phase III topline results from the global ReSPECT clinical trial evaluating Rezzayo for prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hemato...
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 –
CorMedix Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is expanding its institutional pharmaceutical portfolio following the Melinta acquisition, with REZZAYO's phase III prophylaxis data expected soon and DefenCath navigating a temporary reimbursement dip before a 2027 rebound. Pipeline growth includes a TPN indication, and financials remain strong with a $75M buyback program.
CorMedix to Participate in Needham Virtual Healthcare Conference
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threateni...
CorMedix Transcript: The Citizens Life Sciences Conference 2026
REZZAYO's phase III prophylaxis data is expected later in Q2, targeting a $2B+ TAM in transplant patients. DefenCath's launch is strong, with Medicare Advantage seen as a major growth driver, and the Melinta acquisition has stabilized revenue. Operational scaling will follow key clinical milestones.
CorMedix Transcript: Leerink Global Healthcare Conference 2026
The company has evolved into a diversified specialty pharma, expanding its institutional care portfolio and advancing key assets like REZZAYO and DefenCath. Strong clinical results, strategic reimbursement efforts, and a robust financial position support growth, with multiple catalysts expected in the next 12–18 months.
CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M
Ahead of the company’s upcoming investor conference presentations next week, CorMedix (CRMD) also maintains its FY27 DefenCath sales outlook of $150M-$170M.
CorMedix price target lowered to $13 from $15 at Leerink
Leerink lowered the firm’s price target on CorMedix (CRMD) to $13 from $15 and keeps an Outperform rating on the shares.
CorMedix stock drops after earnings: is this dip a buy before key catalyst?
CorMedix (NASDAQ: CRMD) opened meaningfully down on March 5th after reporting a massive swing to profitability but reaffirming 2026 guidance that failed to impress shareholders. The biopharmaceutical ...
CorMedix Earnings Call Transcript: Q4 2025
2025 saw record revenue growth and the Melinta acquisition, with strong Q4 results and robust cash flow. 2026 guidance is affirmed, though price erosion is expected post-TDAPA, and new product catalysts are anticipated. Active share repurchases and a strong pipeline support long-term growth.
CorMedix reports Q4 EPS 16c vs 20c last year
Reports Q4 revenue $128.615M, consensus $127.02M. Joe Todisco, CorMedix (CRMD) Chairman and CEO, commented, “I am proud of the Company’s progress over the past year as we have accelerated the
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Sched...
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr...
CorMedix to Participate in Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Transcript: Investor Day 2026
The company has transformed into a diversified specialty pharma platform, achieving record sales and integrating Melinta to expand its anti-infective portfolio. Rezzayo and DefenCath are positioned for significant growth in high-risk patient populations, with strong clinical and payer support, and multiple late-stage trials underway to address large unmet needs.
CorMedix board authorizes share repurchase program of up to $75M
CorMedix (CRMD) Therapeutics announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company’s outstanding common ...
CorMedix Therapeutics Announces Share Repurchase Program
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...
CorMedix price target lowered to $13 from $18 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on CorMedix (CRMD) to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations have been reset following
CorMedix price target lowered to $13 from $22 at RBC Capital
RBC Capital lowered the firm’s price target on CorMedix (CRMD) to $13 from $22 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies
CorMedix Transcript: 44th Annual J.P. Morgan Healthcare Conference
Record 2025 revenue was driven by DefenCath and Melinta, with 2026 guidance reflecting a transitional reimbursement period. Growth is expected from Rezzayo’s phase 3 readout, DefenCath’s TPN expansion, and strategic business development, supported by strong cash and IP positions.
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre...